Today's Information

Provided by: SYNMOSA BIOPHARMA CORPORATION
SEQ_NO 1 Date of announcement 2022/05/25 Time of announcement 18:20:14
Subject
 Synmosa's 2022 Shareholders' Meeting Major Resolutions
Shareholders' Meeting
Date of events 2022/05/25 To which item it meets paragraph 18
Statement
1.Date of the shareholders' meeting:2022/05/25
2.Important resolutions  I.Profit distribution/deficit compensation:
Approved the adoption of the proposal for distribution of 2021 profits
3.Important resolutions II.Amendments of the company charter:
Approved the amendment of certain provisions of "The Company's Articles
of Incorporation".
4.Important resolutions III.Business report and financial statements:
Approved the 2021 Business Report and Financial Statements
5.Important resolutions IV.Election for directors and supervisors:
Approved the comprehensive Re-election of Directors (Including Independent
Directors).
6.Important resolutions V.Other matters:
Discussion Items
(1)Proposal to issue new shares for capital increase from earnings.
(2)Proposal to amendment of certain provisions of the
"Regulations Governing
Making of Endorsements/Guarantees".
(3)Proposal to amendment of certain provisions of the
"Regulations Governing
Loaning of Funds".
(4)Proposal to amendment of certain provisions of the
"Guidelines for
Derivatives Trading".
(5)Proposal to amendment of certain provisions of the
"Procedures for Director
Appointment".
(6)Proposal to the abolishment and re-establishment of the
"Rules of Procedure
for Shareholders Meetings" case.
Other matters:
Approved the"lifting of non-competition restrictions on newly appointed
directors (including independent directors) and their representatives"case.
7.Any other matters that need to be specified:None

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Synmosa Biopharma Corporation published this content on 25 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 May 2022 16:11:30 UTC.